



**GENAISSANCE
PHARMACEUTICALS**

FIVE SCIENCE PARK
NEW HAVEN, CT 06511
TEL. 203.773.1450
FAX. 203.562.9377
WWW.GENAISSANCE.COM

To: Commissioner for Patents
Date: May 27, 2004
Company: U.S. Patent & Trademark Office
Pages: 4 (Including cover sheet)

Fax Number: 703.872.9306
From: Eileen McCaughern
Subject: Application No. 09/856,803

RECEIVED
CENTRAL FAX CENTER

MAY 27 2004

OFFICIAL

Please see attached.

The document(s) accompanying this facsimile may contain information from Genaissance Pharmaceuticals that is confidential, proprietary, and/or legally privileged. The information is intended only for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or the taking of any action in reliance on the contents of this faxed information is strictly prohibited, and the document(s) should be returned to this company immediately. If you have received this fax in error, please notify us by telephone immediately, so that Genaissance may arrange for the return of the original document(s) at no cost to you.

Docket No. MWH-0029US
U.S. Appl. No. 09/856,803

RECEIVED
CENTRAL FAX CENTER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 27 2004

OFFICIAL

In re Application of: Stephen B. Liggett
Application No.: 09/856,803
Filed: May 25, 2001 (35 U.S.C. § 371 of PCT/US99/27963, filed November 24, 1999, which claims benefit of U.S. Appl. No. 60/109,886, filed November 25, 1998)
Confirmation No.: 3706
Group No.: 1634
Examiner: Myers, C.
For: **POLYMORPHISMS IN THE 5' LEADER CISTRON OF THE β_2 -ADRENERGIC RECEPTOR**

Commissioner for Patents

Certificate of Facsimile Transmission

I hereby certify under 37 C.F.R. § 1.8 that this correspondence is being transmitted by facsimile to the United States Patent and Trademark Office, Commissioner for Patents, TC 1600, at (703) 872-9306, on May 27, 2004.


Eileen McCaughy

AMENDMENT

Please amend the application as follows:

Amendments to the Specification begin on page 2 of this paper.

Remarks begin on page 3 of this paper.